

Resource Summary Report

Generated by [RRID](#) on Aug 4, 2026

BD Biosciences: FACSCalibur Flow Cytometry System

RRID:SCR_000401

Type: Tool

Proper Citation

BD Biosciences: FACSCalibur Flow Cytometry System (RRID:SCR_000401)

Resource Information

URL:

https://www.bdbiosciences.com/documents/FACSCalibur_FlowCytometry_TechSpec.pdf

Proper Citation: BD Biosciences: FACSCalibur Flow Cytometry System (RRID:SCR_000401)

Description: Automated benchtop flow cytometry system. It allows measuring four fluorochrome-conjugates, forward and side scatter., THIS RESOURCE IS NO LONGER IN SERVICE. Documented on September 16,2025.

Abbreviations: BD FACSCalibur system

Synonyms: FACSCalibur flow cytometer

Resource Type: instrument resource

Keywords: flow cytometry, hardware, instrument, equipment

Availability: THIS RESOURCE IS NO LONGER IN SERVICE

Specification URL:

https://drive.google.com/file/d/1v6yeGI7IxHS0_Ezn35dZ9qzu27jIBh52/view?usp=drivesdk

Resource Name: BD Biosciences: FACSCalibur Flow Cytometry System

Resource ID: SCR_000401

Alternate IDs: SciRes_000153

Alternate URLs: https://www.bdbiosciences.com/content/dam/bdb/marketing-documents/BD_FACSCalibur_instructions.pdf

License: Commercial license

Record Creation Time: 20220129T080201+0000

Record Last Update: 20260801T190116+0000

Ratings and Alerts

No rating or validation information has been found for BD Biosciences: FACSCalibur Flow Cytometry System.

No alerts have been found for BD Biosciences: FACSCalibur Flow Cytometry System.

Data and Source Information

Source: [SciCrunch Registry](#)

Usage and Citation Metrics

We found 405 mentions in open access literature.

Listed below are recent publications. The full list is available at [RRID](#) .

Greenman M, et al. (2025) Preclinical Activity of Datopotamab Deruxtecan, an Antibody-Drug Conjugate Targeting Trophoblast Cell-Surface Antigen 2, in Uterine Serous Carcinoma. Cancer research communications, 5(5), 774.

Santin NG, et al. (2025) Preclinical Activity of Datopotamab Deruxtecan (Dato-DXd), an Antibody-Drug Conjugate Targeting TROP2, in Poorly Differentiated Endometrial Carcinomas. Cancer research communications, 5(9), 1611.

Zubiaur M, et al. (2025) CD38 deficiency leads to a defective short-lived transcriptomic response to chronic graft-versus-host disease induction, involving purinergic signaling-related genes and distinct transcriptomic signatures associated with lupus. Frontiers in immunology, 16, 1441981.

Cai MY, et al. (2025) Dual regulation of FZD1/7 by IGF2BP3 enhances stem-like properties and carboplatin resistance in triple-negative breast cancer. Cancer letters, 632, 217944.

Pournajaf S, et al. (2025) Fingolimod Inhibits C6 Rat Glioma Proliferation and Migration, Induces Sub-G1 Cell Cycle Arrest, Mitochondrial and Extrinsic Apoptosis In Vitro and Reduces Tumour Growth In Vivo. Clinical and experimental pharmacology & physiology, 52(1), e70012.

Vax E, et al. (2025) A novel Frizzled 7 antibody disrupts the Wnt pathway and inhibits Wilms tumor growth. Frontiers in bioengineering and biotechnology, 13, 1641137.

van der Heide V, et al. (2025) Prolonged but finite antigen presentation promotes reversible defects of "helpless" memory CD8+ T cells. Immunity, 58(7), 1742.

Kawahara N, et al. (2025) Inhibition of glycolysis and stimulation of mitochondrial biogenesis lead to increased ROS levels and cell death in HNF-1 β positive clear cell carcinoma. *Cell death & disease*, 16(1), 879.

Alfaro E, et al. (2024) Endothelial dysfunction and persistent inflammation in severe post-COVID-19 patients: implications for gas exchange. *BMC medicine*, 22(1), 242.

Fukushima H, et al. (2024) Phototruncation cell tracking with near-infrared photoimmunotherapy using heptamethine cyanine dye to visualise migratory dynamics of immune cells. *EBioMedicine*, 102, 105050.

Afsordeh N, et al. (2024) Eslicarbazepine induces apoptosis and cell cycle arrest in C6 glioma cells in vitro and suppresses tumor growth in an intracranial rat model. *BMC cancer*, 24(1), 1099.

Bayat H, et al. (2024) CRISPR/Cas9-mediated deletion of a GA-repeat in human GPM6B leads to disruption of neural cell differentiation from NT2 cells. *Scientific reports*, 14(1), 2136.

Regunath K, et al. (2024) Systematic Characterization of p53-Regulated Long Noncoding RNAs across Human Cancers Reveals Remarkable Heterogeneity among Different Tumor Types. *Molecular cancer research : MCR*, 22(6), 555.

Juarez D, et al. (2023) Statin-induced Mitochondrial Priming Sensitizes Multiple Myeloma Cells to BCL2 and MCL-1 Inhibitors. *Cancer research communications*, 3(12), 2497.

Kato T, et al. (2023) Near-Infrared Photoimmunotherapy Targeting Podoplanin-Expressing Cancer Cells and Cancer-Associated Fibroblasts. *Molecular cancer therapeutics*, 22(1), 75.

Klement JD, et al. (2023) Tumor PD-L1 engages myeloid PD-1 to suppress type I interferon to impair cytotoxic T lymphocyte recruitment. *Cancer cell*, 41(3), 620.

Bayat H, et al. (2023) Synthetic miR-21 decoy circularized by tRNA splicing mechanism inhibited tumorigenesis in glioblastoma in vitro and in vivo models. *Molecular therapy. Nucleic acids*, 32, 432.

Uehara T, et al. (2023) Translocation of nuclear chromatin distribution to the periphery reflects dephosphorylated threonine-821/826 of the retinoblastoma protein (pRb) in T24 cells treated with Bacillus Calmette-Guérin. *Cytotechnology*, 75(1), 49.

Refaat AM, et al. (2023) HNRNPU facilitates antibody class-switch recombination through C-NHEJ promotion and R-loop suppression. *Cell reports*, 42(3), 112284.

Takahashi K, et al. (2023) Brain-specific glycosylation of protein tyrosine phosphatase receptor type Z (PTPRZ) marks a demyelination-associated astrocyte subtype. *Journal of neurochemistry*.